MCID: INT070
MIFTS: 58

Intestinal Obstruction

Categories: Fetal diseases, Gastrointestinal diseases, Genetic diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Intestinal Obstruction

Summaries for Intestinal Obstruction

MedlinePlus : 42 An intestinal obstruction occurs when food or stool cannot move through the intestines. The obstruction can be complete or partial. There are many causes. The most common are adhesions, hernias, cancers, and certain medicines. Symptoms include Severe abdominal pain or cramping Vomiting Bloating Loud bowel sounds Swelling of the abdomen Inability to pass gas Constipation A complete intestinal obstruction is a medical emergency. It often requires surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Intestinal Obstruction is related to volvulus of midgut and intestinal pseudo-obstruction, and has symptoms including nausea and vomiting, abdominal pain and constipation. An important gene associated with Intestinal Obstruction is GDNF (Glial Cell Derived Neurotrophic Factor), and among its related pathways/superpathways is Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include colon, small intestine and liver, and related phenotypes are behavior/neurological and cellular

Related Diseases for Intestinal Obstruction

Diseases in the Intestinal Obstruction family:

Intestinal Pseudo-Obstruction

Diseases related to Intestinal Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 755)
# Related Disease Score Top Affiliating Genes
1 volvulus of midgut 33.5 GUCY2C CRP ALB
2 intestinal pseudo-obstruction 33.4 SGO1 RET EDN3 ACHE
3 hypoganglionosis 33.2 RET GDNF ACHE
4 hirschsprung disease 1 33.0 RET NRTN GDNF EDNRB EDN3 ACHE
5 ileus 32.7 GUCY2C CRP CFTR
6 intussusception 32.4 CRP CFTR ALB
7 constipation 31.0 RET NRTN GUCY2C GDNF FLNA EDNRB
8 intestinal perforation 30.9 NOD2 KRT7 CRP ALB
9 intestinal tuberculosis 30.9 NOD2 CRP ALB
10 teratoma 30.9 KRT7 KRT20 GATA4 CDX2
11 pseudomyxoma peritonei 30.9 KRT7 KRT20 CDX2
12 megacolon 30.8 RET NRTN GDNF EDNRB EDN3 ACHE
13 typhoid fever 30.8 CRP CFTR ALB
14 adenoma 30.7 RET KRT7 KRT20 CDX2
15 diarrhea 30.7 NOD2 GUCY2C FLNA CFTR ALB ACHE
16 cystic teratoma 30.7 KRT7 KRT20 CDX2
17 intestinal disease 30.6 NOD2 CRP CD8A ALB
18 bacterial infectious disease 30.6 NOD2 CRP CFTR CD8A
19 hemorrhoid 30.5 FLNA CRP ALB
20 tuberculous peritonitis 30.5 CRP ALB
21 celiac disease 1 30.5 NOD2 CRP CD8A ALB
22 respiratory failure 30.4 GATA4 CRP CFTR ALB ACHE
23 cholangiocarcinoma 30.4 MTOR KRT7 KRT20 CDX2
24 signet ring cell adenocarcinoma 30.4 KRT7 KRT20 CDX2
25 jejunal adenocarcinoma 30.4 KRT7 KRT20 CDX2
26 intrahepatic cholangiocarcinoma 30.4 KRT7 KRT20 CDX2 ALB
27 appendix adenocarcinoma 30.4 KRT7 KRT20 CDX2
28 horseshoe kidney 30.4 KRT7 KRT20 CDX2
29 mucinous adenocarcinoma 30.4 KRT7 KRT20 CDX2
30 taeniasis 30.3 FLNA CD8A ALB
31 multidrug-resistant tuberculosis 30.3 EDNRB CD8A ALB
32 portal hypertension 30.3 EDNRB CFTR ALB
33 hydronephrosis 30.3 KRT7 GATA4 FLNA CRP ALB
34 duodenitis 30.3 CRP CD8A ALB
35 ovarian brenner tumor 30.3 KRT7 KRT20
36 pneumocystosis 30.3 CRP CD8A ALB
37 splenic disease 30.2 CRP CD8A ALB
38 syphilis 30.2 CRP CD8A ALB
39 vesicoureteral reflux 1 30.2 RET GDNF CRP ALB
40 neuroendocrine tumor 30.2 RET MTOR KRT20 CDX2
41 patent ductus arteriosus 1 30.2 GATA4 FLNA CRP ALB
42 polyneuropathy 30.1 GDNF CRP ALB ACHE
43 exanthem 30.1 MTOR CRP CD8A ALB
44 cystic kidney disease 30.1 MTOR EDNRB CFTR ALB
45 cholangitis 30.1 NOD2 CRP CFTR ALB
46 lung disease 30.1 RET FLNA CRP CFTR CD8A ALB
47 cystitis 30.1 KRT7 KRT20 GDNF CRP CDX2
48 gallbladder disease 30.1 KRT7 CRP CFTR ALB
49 lung cancer susceptibility 3 30.1 RET MTOR KRT7 KRT20 CDX2 CD8A
50 autosomal dominant polycystic kidney disease 30.1 MTOR EDNRB CFTR ALB

Comorbidity relations with Intestinal Obstruction via Phenotypic Disease Network (PDN): (show top 50) (show all 55)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Anxiety
Ascending Colon Cancer Bronchitis
Candidiasis Cecal Benign Neoplasm
Cervical Cancer Chronic Intestinal Vascular Insufficiency
Chylomicron Retention Disease Colorectal Cancer
Crohn's Disease Decubitus Ulcer
Deficiency Anemia Descending Colon Cancer
Enterovesical Fistula Esophageal Disease
Esophagitis Familial Atrial Fibrillation
Gastric Cancer Gastrointestinal System Cancer
Generalized Atherosclerosis Heart Disease
Hepatic Flexure Cancer Hydronephrosis
Hypertension, Essential Hypothyroidism
Inflammatory Bowel Disease 1 Intestinal Disease
Intestinal Perforation Iron Deficiency Anemia
Irritable Bowel Syndrome Jejunal Cancer
Kidney Disease Marasmus
Neutropenia Osteoporosis
Ovarian Cancer Pancreatic Cancer
Pancreatitis, Hereditary Paralytic Ileus
Peritonitis Postgastrectomy Syndrome
Protein-Energy Malnutrition Radiation Cystitis
Rectosigmoid Junction Neoplasm Schizophreniform Disorder

Graphical network of the top 20 diseases related to Intestinal Obstruction:



Diseases related to Intestinal Obstruction

Symptoms & Phenotypes for Intestinal Obstruction

UMLS symptoms related to Intestinal Obstruction:


nausea and vomiting, abdominal pain, constipation, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Intestinal Obstruction:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.26 ACHE CFTR EDN3 EDNRB FLNA GDNF
2 cellular MP:0005384 10.25 ALB CD8A CDX2 EDNRB FLNA GATA4
3 digestive/alimentary MP:0005381 10.22 ALB CDX2 CFTR EDN3 EDNRB FLNA
4 cardiovascular system MP:0005385 10.16 ALB CDX2 CRP EDNRB FLNA GATA4
5 homeostasis/metabolism MP:0005376 10.13 ACHE ALB CDX2 CFTR CRP EDNRB
6 endocrine/exocrine gland MP:0005379 10.11 ALB CD8A CDX2 CFTR EDNRB GATA4
7 growth/size/body region MP:0005378 10.1 ACHE CDX2 CFTR EDNRB FLNA GATA4
8 immune system MP:0005387 9.93 ALB CD8A CFTR CRP EDNRB FLNA
9 mortality/aging MP:0010768 9.86 ACHE ALB CD8A CDX2 CFTR EDN3
10 muscle MP:0005369 9.23 ACHE ALB EDNRB GATA4 GDNF MTOR

Drugs & Therapeutics for Intestinal Obstruction

Drugs for Intestinal Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 208)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
3
Bisacodyl Approved Phase 4 603-50-9
4
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
5
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
6
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
8
Phentermine Approved, Illicit Phase 4 122-09-8 4771
9
Linagliptin Approved Phase 4 668270-12-0 10096344
10
Empagliflozin Approved Phase 4 864070-44-0
11
Liraglutide Approved Phase 4 204656-20-2 44147092
12
Canagliflozin Approved Phase 4 842133-18-0
13
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
14
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
15
Morphine Approved, Investigational Phase 4 57-27-2 5288826
16
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
17
Cimetropium Experimental, Investigational Phase 4 150521-16-7
18 Parasympatholytics Phase 4
19 Cholinergic Antagonists Phase 4
20 Cola Phase 4
21 Nutrients Phase 4
22 Anti-Infective Agents Phase 4
23 Central Nervous System Stimulants Phase 4
24 beta-Lactamase Inhibitors Phase 4
25 Adrenergic Agents Phase 4
26 Sympathomimetics Phase 4
27 Appetite Depressants Phase 4
28 Liver Extracts Phase 4
29 Laxatives Phase 4
30 Cathartics Phase 4
31 Polyethylene glycol 3350 Phase 4
32 Hormones Phase 4
33 Hormone Antagonists Phase 4
34 Anti-Obesity Agents Phase 4
35 Dipeptidyl-Peptidase IV Inhibitors Phase 4
36
protease inhibitors Phase 4
37 Sodium-Glucose Transporter 2 Inhibitors Phase 4
38 Hypoglycemic Agents Phase 4
39 Incretins Phase 4
40 HIV Protease Inhibitors Phase 4
41 Lipid Regulating Agents Phase 4
42 Sitagliptin Phosphate Phase 4
43 Anti-Inflammatory Agents Phase 4
44 Anesthetics Phase 4
45 Narcotics Phase 4
46 Analgesics, Opioid Phase 4
47 Analgesics Phase 4
48 Anti-Inflammatory Agents, Non-Steroidal Phase 4
49 Anesthetics, Local Phase 4
50
Allantoin Approved Phase 3 97-59-6 204

Interventional clinical trials:

(show top 50) (show all 153)
# Name Status NCT ID Phase Drugs
1 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
2 Phase 4 Evaluation of SurgiWrapTM to Minimize Soft Tissue Attachment & Reduce the Incidence of Early Post-Operative Bowel Obstruction in Colorectal Surgery Completed NCT00531739 Phase 4
3 Gastrografin Use in Small Bowel Obstruction Caused by Adherences Completed NCT00601809 Phase 4 Gastrografin®: G
4 Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction Completed NCT00389116 Phase 4 gastrograffin;water
5 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Completed NCT01507246 Phase 4 IV morphine sulfate;EXPAREL (bupivacaine liposome injectable suspension)
6 High-volume Polyethylene Glycol Solution (PEG) Versus Low-volume PEG Plus Stimulant Laxative Versus Sennosides for Colon Cleansing Before Colonoscopy: a Randomized, Single Blinded Study Completed NCT01531140 Phase 4 polyethylene glycol +Bisacodyl;Polyethylene glycol;Sennosides
7 Prospective, Multi-centers, Investigator Sponsored, Randomized Controlled Trial Towards Identifying the Effect of Somatostatin Treatment in Early Postoperative Simple Small Bowel Obstruction Completed NCT01082627 Phase 4 Somatostatin
8 Effect of Deep Versus Moderate Neuromuscular Blockade on Peak Airway Pressures During Elective Laparoscopic Surgery Completed NCT02812186 Phase 4 Rocuronium
9 A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy in Patients With Massive Overt Obscure Gastrointestinal Bleeding Completed NCT01654770 Phase 4
10 Non Operative Treatment for Acute Appendicitis: Study on Efficacy and Safety of Antibiotic Treatment (Amoxicillin and Clavulanic Acid) in Patients With Right Sided Lower Abdominal Pain Completed NCT01096927 Phase 4 Amoxicillin and Clavulanic Acid
11 Cost- Effectiveness and Cost-utility of Laparoscopic Versus Open Repair of Ventral Hernia: Randomized Clinical Trial Completed NCT01778387 Phase 4
12 A Simple Oral Nutrition Protocol Reduces Length of Stay in Patients With Regular Radical Cystectomy Completed NCT01777126 Phase 4
13 Effectiveness and Tolerability of Phentermine in the Reduction of Intrahepatic Fat Infiltration, Adipose Tissue and Postoperative Complications in Patients Under Bariatric Surgery Recruiting NCT03849729 Phase 4 Phentermine
14 The Use of Gastrografin to Help Alleviate Bowel Obstruction Related to Poor Bowel Motility in Gastroschisis Patients. Recruiting NCT03334578 Phase 4 Gastrografin
15 Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit Recruiting NCT04210427 Phase 4 Polyethylene Glycol 3350
16 Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes vs Best Medical Treatment Active, not recruiting NCT02041234 Phase 4 Incretin analogues;Xenical;SGLT2 inhibitors;DPP-4 Inhibitors
17 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation of Bupivacaine, EXPAREL(R): A Phase 4 Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy (IMPROVE-Lap Colectomy) Terminated NCT02058290 Phase 4 IV morphine sulfate or Sponsor-approved equivalent;EXPAREL
18 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Terminated NCT01507233 Phase 4 IV morphine sulfate;EXPAREL (bupivacaine liposome injectable suspension)
19 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Terminated NCT01507220 Phase 4 morphine sulfate;bupivacaine liposome extended-release injectable suspension
20 Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy Withdrawn NCT01401387 Phase 4
21 Prospective Multicenter Trial for Anti-adhesion Effect of GUARDIX-SGⓇ Following Radical Gastrectomy in Patients With Gastric Cancer. Unknown status NCT02198898 Phase 3
22 Bariatric Arterial Embolization for Morbid Obesity Unknown status NCT02786108 Phase 3
23 A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase IIB Study of Oral Naloxone for the Treatment of Opioid-Induced Constipation in Patients With Chronic, Non-malignant Pain or Malignant Pain Unknown status NCT00020605 Phase 3 naloxone hydrochloride
24 A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI) in Subjects Undergoing Abdominal Operation Unknown status NCT01863407 Phase 3 DAM;Normal Saline
25 Endolaparoscopic Versus Immediate Surgery for Obstructing Colorectal Cancers: A Randomised Trial Unknown status NCT00164879 Phase 3
26 Phase III, Multicentre, Randomised, Double-blind, Comparative Study to Assess the Efficacy and Safety of Lanreotide 30 mg Versus Placebo as a Palliative Treatment of Clinical Symptoms Associated With Intestinal Obstruction Due to Peritoneal Carcinomatosis in Inoperable Patients. Completed NCT00216372 Phase 3 Lanreotide (microparticle formulation)
27 Effects of Delayed Enteral Nutrition on Inflammatory Responses and Immune Function Competence in Critically Ill Patients With Prolonged Fasting Completed NCT01834430 Phase 3
28 Endoscopic Stenting and Elective Surgery Versus Emergency Surgery for Left-sided Malignant Colonic Obstruction: A Prospective Randomized Trial. Completed NCT00758186 Phase 3
29 Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction in Patients With Gastric Cancer. A Randomized Clinical Trial Completed NCT00529412 Phase 3
30 Randomized Phase III Study of 5-FU Continuous Infusion (5FUci) Versus MTX+5-FU Sequential Therapy (MF) in Gastric Cancer With Peritoneal Metastasis (JCOG0106-MF, MF/5FU) Completed NCT00149201 Phase 3 5-FU continuous infusion;MTX + 5-FU sequential therapy
31 Outcome of Palliative Management of Malignant Large Bowel Obstruction With Colorectal Stents or Surgery Completed NCT00140868 Phase 3
32 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed NCT00327444 Phase 2, Phase 3 aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Placebo;aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
33 Effects of the Abbreviation of Preoperative Fasting With Carbohydrates and Hydrolized Proteins on the Inflammatory Response and Insulin Resistance After Major Abdominal Operations Completed NCT01563965 Phase 3
34 Phase 3 Study of Antibiotic Prophylaxis Use Prior Emergent Surgery, Because of Acute Appendicitis Completed NCT01524081 Phase 3 Metronidazole, Cefuroxime;Amoxicillin (+ clavulanic acid) and Fluconazole;Placebo;Placebo
35 The Therapeutic Role of Gastrografin for Treating Small Bowel Obstruction in Children: A Multi-Centre Canadian Prospective Study Recruiting NCT03573921 Phase 2, Phase 3 Gastrografin
36 A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in the Prevention of Acute Enteritis in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy Withdrawn NCT01473290 Phase 3
37 Use of Gastrografin in the Management of Fecal Impaction in Patients With Severe Chronic Constipation: A Double-blinded Randomized Controlled Trial Unknown status NCT02784093 Phase 2 Gastrografin
38 Chinese PLA Generation Hospital Unknown status NCT03095001 Phase 2 Bevacizumab;Carboplatin;paclitaxel
39 An International, Multicentric, Prospective, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 MG Associated to Standard of Care in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction Completed NCT02275338 Phase 2 Lanreotide Autogel
40 Prospective Study to Assess the Efficacy and Safety of Lanreotide 120 mg as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients Completed NCT01076803 Phase 2 Lanreotide (acetate)
41 Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis Completed NCT00332696 Phase 2 Octreotide LAR;Octreotide (Immediate release);methylprednisolone;Placebo
42 The Efficacy and Safety of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Adhesions After Laparoscopic Gynecological Surgery: a Randomized Controlled Trial Completed NCT02166554 Phase 1, Phase 2
43 A Multicenter, Open-label, Single-arm Study of the Efficacy and Safety of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites Completed NCT00396591 Phase 2 Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
44 A Controlled Randomized Multicenter Study to Assess the Safety and Performance of Adhibit™ Adhesion Prevention Gel in Myomectomy Surgery Completed NCT00562471 Phase 1, Phase 2
45 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
46 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
47 Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study Completed NCT00004895 Phase 2 octreotide acetate
48 A Multicenter, Randomized, Double-blind, Parallel-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum-resistant and topotecan-and/or Liposomal Doxorubicin-resistant Advanced Ovarian Cancer Completed NCT00327171 Phase 2 Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®);Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
49 A Multicenter, Open-label, Single-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum- and Erlotinib-resistant Locally Advanced or Metastatic Non-small-cell Lung Adenocarcinoma Completed NCT00284141 Phase 2 Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
50 A Pilot Randomised Study to Compare Combination Antibiotic Therapy (Ciprofloxacin, Doxycycline and Hydroxychloroquine) With Standard Therapy (Budesonide) in the Treatment of Active Crohn's Disease Completed NCT01783106 Phase 2 Ciprofloxacin;Doxycycline;Hydroxychloroquine;Budesonide

Search NIH Clinical Center for Intestinal Obstruction

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Heavy mineral oil
Mineral Oil
Mineral Oil, Light
MINERAL OIL,EXTRA HEAVY
MINERAL OIL,MEDIUM
MINERAL OIL,REFINED

Cochrane evidence based reviews: intestinal obstruction

Genetic Tests for Intestinal Obstruction

Genetic tests related to Intestinal Obstruction:

# Genetic test Affiliating Genes
1 Intestinal Obstruction 29

Anatomical Context for Intestinal Obstruction

MalaCards organs/tissues related to Intestinal Obstruction:

40
Colon, Small Intestine, Liver, Pancreas, Lung, Kidney, Appendix

Publications for Intestinal Obstruction

Articles related to Intestinal Obstruction:

(show top 50) (show all 11430)
# Title Authors PMID Year
1
Neonate With Emesis After Every Feed. 42
32471574 2020
2
Neonate With Vomiting and Jaundice. 42
32471575 2020
3
Clinical efficacy and safety of somatostatin in the treatment of early postoperative inflammatory small bowel obstruction: A protocol for systematic review and meta analysis. 42
32443374 2020
4
Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies. 54 61
18782827 2008
5
Impact of nutrition on phenotype in CFTR-deficient mice. 54 61
17805210 2007
6
Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. 54 61
17030173 2006
7
Distinct pattern of lung gene expression in the Cftr-KO mice developing spontaneous lung disease compared with their littermate controls. 61 54
16418321 2006
8
Distal intestinal obstruction syndrome in adults with cystic fibrosis. 54 61
15181619 2004
9
Liver cirrhosis and portal hypertension in cystic fibrosis. 61 54
14501614 2003
10
Gdnf haploinsufficiency causes Hirschsprung-like intestinal obstruction and early-onset lethality in mice. 54 61
11774071 2002
11
Cellular localization of the cystic fibrosis transmembrane conductance regulator in mouse intestinal tract. 61 54
10959824 2000
12
[Gastrointestinal complications of adult patients with cystic fibrosis]. 61 54
10494610 1999
13
Clinical and genetic risk factors for cystic fibrosis-related liver disease. 54 61
9917439 1999
14
Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. 61 54
8589719 1996
15
Experimental Models of Partial Intestinal Obstruction in Young Mice: Establishment, and Evaluation. 61
32283334 2020
16
Case Report: Phytobezoar Causing Gastric Outlet Obstruction as a Late Complication After Biliopancreatic Diversion with Duodenal Switch. 61
32232642 2020
17
Multiple Magnetic Beads Cause Intestinal Obstruction. 61
32349037 2020
18
Network Pharmacology and Bioactive Equivalence Assessment Integrated Strategy Driven Q-markers Discovery for Da-Cheng-Qi Decoction to Attenuate Intestinal Obstruction. 61
32464544 2020
19
Pouch of Douglas internal hernia successfully treated laparoscopically. 61
31793455 2020
20
Palliative treatment for bowel obstruction in ovarian cancer: a meta-analysis. 61
32445066 2020
21
Characteristics of Intestinal Volvulus and Risk of Mortality in Malawi. 61
32100066 2020
22
Long-term Results of the Side-to-side Isoperistaltic Strictureplasty in Crohn Disease: 25-year Follow-up and Outcomes. 61
30720502 2020
23
[The safety and efficacy of radical surgery after modified total neoadjuvant therapy for locally advanced rectal cancer]. 61
32575948 2020
24
Malignant Brenner tumour of the ovary manifesting as distal intestinal obstruction and perforation. 61
32532918 2020
25
The Efficacy of Over-the-Scope Clip Closure for Gastrointestinal Iatrogenic Perforation During Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Pancreaticobiliary Diseases. 61
32141973 2020
26
Chilaiditi Sign and Chilaiditi Syndrome in Pregnancy. 61
32532582 2020
27
Hyperglycaemia and the risk of post-surgical adhesion. 61
32536284 2020
28
Aetiologies and outcomes of patients with abdominal pain presenting to an emergency department of a tertiary hospital in Tanzania: a prospective cohort study. 61
32503438 2020
29
Incarcerated femoral hernia treated with elective totally extraperitoneal repair: a case report. 61
32577212 2020
30
Histopathologic Spectrum of Neuromuscular and Vascular Hamartoma With Special Reference to the Vasculopathic Phenomenon. 61
31760840 2020
31
Exploring the evidence-practice gap in the use of plain radiography for acute abdominal pain and intestinal obstruction: a systematic review and meta-analysis. 61
32141947 2020
32
Gastrolithiasis with incomplete intestinal obstruction in the perioperative period of percutaneous transluminal coronary intervention: one case report. 61
32576009 2020
33
Current practice of rapid sequence induction in adults: A national survey among anesthesiologists in Spain. 61
32564884 2020
34
[Abdominal imaging in cystic fibrosis]. 61
32495009 2020
35
Disseminated Histoplasmosis and Miliary Tuberculosis Imitating Colon Cancer in Patient with HIV Who Refuses to Antirretroviral Treatment. 61
32385592 2020
36
Pathogenesis and Clinical Management of Mesenteric Fibrosis in Small Intestinal Neuroendocine Neoplasms: A Systematic Review. 61
32521677 2020
37
[Ileocolonic intussusception in an adolescent patient with cystic fibrosis]. 61
32470278 2020
38
Neonatal thrombotic microangiopathy secondary to factor I variant with Hirschsprung disease. 61
32514992 2020
39
Diagnostic performance and role of the contrast enema for low intestinal obstruction in neonates. 61
32572600 2020
40
Radiographic findings predictive of irreducibility and surgical resection in ileocolic intussusception. 61
32519054 2020
41
Proteus Syndrome, a rare case with an unusual presentation: Case report. 61
32563816 2020
42
Small bowel knots. 61
32538120 2020
43
Bowel perforation of ventriculoperitoneal shunt catheter: endoscopically treated two cases. 61
32519129 2020
44
Type II enteropathy-associated T cell lymphoma in the duodenum: A rare case report. 61
32501967 2020
45
Male infant patient with a mesenteric cyst in the greater and lesser omenta: a case report. 61
32393165 2020
46
Missed opportunity of deworming a Maasai boy from nomadic family leading to life threatening intestinal obstruction. 61
32494353 2020
47
Upper Gastrointestinal Bleeding Due to a Duodenal Metastasis from Primary Testicular Squamous Cell Carcinoma. 61
32392185 2020
48
Deep infiltrating endometriosis: An atypical cause of intestinal obstruction. 61
31806253 2020
49
Risk of bowel obstruction in patients with mesenteric/peritoneal disease receiving peptide receptor radionuclide therapy (PRRT). 61
32444368 2020
50
Malnutrition in Acute Care Surgery Patients in Rwanda. 61
31897691 2020

Variations for Intestinal Obstruction

ClinVar genetic disease variations for Intestinal Obstruction:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 GATA4 NM_002052.5(GATA4):c.94G>C (p.Ala32Pro)SNV Uncertain significance 599008 rs773545065 8:11565915-11565915 8:11708406-11708406
2 ERF NM_006494.4(ERF):c.1636C>T (p.Arg546Ter)SNV Uncertain significance 599007 rs764412749 19:42752628-42752628 19:42248476-42248476

Expression for Intestinal Obstruction

Search GEO for disease gene expression data for Intestinal Obstruction.

Pathways for Intestinal Obstruction

Pathways related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.05 GATA4 CFTR CDX2 ALB

GO Terms for Intestinal Obstruction

Biological processes related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.88 NOD2 GDNF EDNRB EDN3 CDX2
2 nervous system development GO:0007399 9.85 RET NRTN GDNF EDNRB ACHE
3 cellular response to starvation GO:0009267 9.61 MTOR KRT20 ALB
4 positive regulation of cell differentiation GO:0045597 9.5 GDNF EDN3 CDX2
5 intestinal epithelial cell differentiation GO:0060575 9.4 GATA4 CDX2
6 positive regulation of neuron maturation GO:0014042 9.37 RET MTOR
7 vein smooth muscle contraction GO:0014826 9.26 EDNRB EDN3
8 posterior midgut development GO:0007497 9.16 RET EDNRB
9 enteric nervous system development GO:0048484 9.13 RET GDNF EDNRB
10 neural crest cell migration GO:0001755 9.02 RET NRTN GDNF EDNRB EDN3

Molecular functions related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 toxic substance binding GO:0015643 8.62 GUCY2C ALB

Sources for Intestinal Obstruction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....